SOS1-inspired hydrocarbon-stapled peptide as a pan-Ras inhibitor

Bioorg Chem. 2023 Jun:135:106500. doi: 10.1016/j.bioorg.2023.106500. Epub 2023 Mar 25.

Abstract

Blocking the interaction between Ras and Son of Sevenless homolog 1 (SOS1) has been an attractive therapeutic strategy for treating cancers involving oncogenic Ras mutations. K-Ras mutation is the most common in Ras-driven cancers, accounting for 86%, with N-Ras mutation and H-Ras mutation accounting for 11% and 3%, respectively. Here, we report the design and synthesis of a series of hydrocarbon-stapled peptides to mimic the alpha-helix of SOS1 as pan-Ras inhibitors. Among these stapled peptides, SSOSH-5 was identified to maintain a well-constrained alpha-helical structure and bind to H-Ras with high affinity. SSOSH-5 was furthermore validated to bind with Ras similarly to the parent linear peptide through structural modeling analysis. This optimized stapled peptide was proven to be capable of effectively inhibiting the proliferation of pan-Ras-mutated cancer cells and inducing apoptosis in a dose-dependent manner by modulating downstream kinase signaling. Of note, SSOSH-5 exhibited a high capability of crossing cell membranes and strong proteolytic resistance. We demonstrated that the peptide stapling strategy is a feasible approach for developing peptide-based pan-Ras inhibitors. Furthermore, we expect that SSOSH-5 can be further characterized and optimized for the treatment of Ras-driven cancers.

Keywords: Ras mutant cancer cells; Ras–SOS1 interaction; Stapled peptides; Undruggable protein–protein interactions; pan-Ras inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Humans
  • Mutation
  • Neoplasms*
  • Peptides / pharmacology
  • SOS1 Protein / chemistry
  • SOS1 Protein / genetics
  • SOS1 Protein / metabolism
  • Signal Transduction

Substances

  • SOS1 Protein
  • Peptides
  • Antineoplastic Agents